Atopic Dermatitis (AD) Models
Available Atopic Dermatitis Models
——T-cell mediated chronic skin inflammation model
——contact hypersensitivity-based AD-like response model
——strong Th2 cytokine-driven AD model
Key Readouts and Assay Capabilities
- Clinical scoring (erythema, edema, scaling, scratching behavior)
- Histopathology (H&E staining, epidermal thickness)
- Serum biomarkers (IgE, cytokines such as IL-4, IL-13)
- Immune profiling (Th1/Th2/Th17 responses)
- Molecular assays (qPCR, Western blot, immunohistochemistry)
Overview of Atopic Dermatitis (AD)
Atopic dermatitis (AD), also known as atopic eczema, is a chronic, relapsing inflammatory skin disorder characterized by pruritus, eczematous lesions, and impaired skin barrier function. It affects both pediatric and adult populations worldwide, with increasing prevalence in recent decades.
The pathogenesis of AD is complex and involves a combination of epidermal barrier dysfunction, immune dysregulation (predominantly Th2-skewed responses), and environmental triggers. Elevated levels of cytokines such as IL-4 and IL-13 play a central role in disease progression.
Fig. 1. Overview of the pathophysiology of atopic dermatitis (AD) (de Bruin-Weller MS, Boesjes CM, et al. 2026).
Due to the multifactorial and heterogeneous nature of AD, no single animal model can fully recapitulate the human condition. Therefore, multiple experimental models are required to capture distinct pathological features and support mechanism-driven drug development.
Comparison of Common Atopic Dermatitis Models
| Model | Key Features | Advantages | Limitations | Suitable Drug Types |
| Oxazolone-Induced AD Model | Th2-dominant inflammation, epidermal thickening | Rapid induction, reproducible | Mainly acute/chronic mixed response | Small molecules / corticosteroids, immunosuppressants |
| DNFB-Induced AD Model | Contact hypersensitivity with AD-like lesions | Simple and cost-effective | Strong irritant component | Topical drugs, anti-allergic compounds |
| MC903-Induced AD Model | Strong Th2 immune activation (IL-4/IL-13 axis) | High consistency, stable phenotype | Limited mechanistic diversity | Monoclonal antibodies targeting IL-4/IL-13 |
Why Choose Creative Bioarray's Atopic Dermatitis (AD) Models
Multi-Model Platform
Access to diverse ADin vivo models for different research needs
Study Design Support
Guidance on model selection based on drug mechanism and targets
Comprehensive Readouts
Integrated efficacy + mechanism evaluation system
Translational Focus
Model strategies aligned with clinical relevance and regulatory expectations
FAQ
What is the most commonly used animal model for atopic dermatitis research?
There is no one single "best" atopic dermatitis model. Various models mimic different facets of human disease. Oxazolone/DNFB models are often used to assess inflammatory and topical route efficacy, while MC903-induced AD model better mimics Th2-driven immune responses.
Which AD model is most suitable for biologic drug evaluation?
The MC903-induced atopic dermatitis model is generally preferred for biologics targeting Th2-related pathways, such as IL-4 and IL-13. It provides a more consistent immune response that is relevant for evaluating targeted therapies.
What are the differences between Oxazolone, DNFB, and MC903 models?
These three AD preclinical models differ mainly in their immune mechanisms and applications:
- Oxazolone model: mixed Th1/Th2 inflammatory response
- DNFB model: contact hypersensitivity-driven skin inflammation
- MC903 model: strong Th2 cytokine-dominant response
Each model is used for different drug evaluation needs depending on mechanism of action.
How do I know which AD model is right for me?
Typically, small molecules/topical agents are tested in Oxazolone or DNFB models while biologics are tested in MC903-induced AD model. Let Creative Bioarray help you determine the right atopic dermatitis model service.
Start Your AD Model Study Today
Choosing the right atopic dermatitis animal model is key to generating reliable preclinical results. Creative Bioarray provides customized AD model solutions tailored to your drug type and research goals.
Reference
- de Bruin-Weller MS, Boesjes CM, et al. Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions. Allergy. 2026. 81(2):326-344.